文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌图像引导调强放疗后的泌尿生活质量结局

Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer.
PubMed 文献 · Adv Radiat Oncol · 2016-10-29

研究纳入3602例接受图像引导调强放疗(IG-IMRT)的前列腺癌男性,前列腺和精囊典型剂量为8100 cGy分45次。中位随访24个月,尿失禁累积发生率较低,部分基线有尿失禁或下尿路症状者症状改善,中重度IPSS患者评分显著下降。

要点

  • IG-IMRT后尿失禁发生率相对较低,基线无尿失禁者占85.7%,随访末为80.6%。
  • 部分基线轻度尿失禁者随访期间完全控尿,显著尿失禁者也有部分缓解或改善。
  • 中度和重度IPSS患者平均IPSS评分均显著下降。

核心结论

  • IG-IMRT治疗临床局限期前列腺癌与相对较低的尿失禁发生率相关。
  • 部分基线有尿失禁及中重度IPSS的患者在IG-IMRT后症状改善,机制未明。

研究设计与样本

  • 前瞻性维护数据库纳入大型泌尿专科集团实践中诊断前列腺癌并接受IG-IMRT的男性。
  • 前列腺和精囊典型放疗剂量为8100 cGy分45次。
  • 采用标准化尿失禁分级和国际前列腺症状评分(IPSS)在基线和每次随访时自评。
  • 分析3602例 eligible 男性,中位随访24个月(范围12.0-41.0个月)。

主要发现

  • 基线时3086例(85.7%)无尿失禁,479例(13.3%)轻度尿失禁(无需尿垫),37例(1.0%)显著尿失禁需尿垫或影响日常活动。
  • 随访末上述比例分别为80.6%、17.4%和2.0%。
  • 54.1%的基线轻度尿失禁者随访期间完全控尿。
  • 显著尿失禁者中29.7%报告缓解,27.0%报告改善且无需尿垫。
  • 1276例中度IPSS者平均IPSS从12降至9.8(P < .001);233例重度IPSS者平均IPSS从24降至13(P < .001)。

临床怎么用

  • IG-IMRT可作为临床局限期前列腺癌的放疗选择,尿失禁风险相对较低。
  • 治疗前应评估基线尿失禁分级和IPSS,以便随访比较和咨询。
  • 对基线有尿失禁或中重度下尿路症状者,可告知部分患者放疗后症状可能改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Quality of life (QoL) outcomes play a major role in the treatment selection for prostate cancer (CaP). We evaluated the urinary QoL outcomes in men who were treated with image-guided intensity-modulated radiation therapy (IG-IMRT) for CaP. METHODS AND MATERIALS: We enrolled men who were diagnosed with CaP and underwent IG-IMRT in a large urological group practice into a prospectively maintained database. The typical radiation treatment dosage to prostates and seminal vesicles was 8100 cGy in 45 fractions. Urinary QoL was self-assessed using the standardized incontinence grade and International Prostate Symptom Score (IPSS) at baseline and at each follow-up visit. We evaluated the cumulative incidence of urinary incontinence and changes in both continence and IPSS over time. RESULTS: Of the 3602 men who were eligible for analysis, 3086 (85.7%) had no urinary incontinence; 479 (13.3 %) had minimal incontinence (no requirement for pads), and 37 (1.0 %) had significant urinary incontinence that required the use of pads or interfered with activities of daily living, at baseline. After a median follow-up of 24 months (range: 12.0-41.0 months), these numbers were 80.6%, 17.4%, and 2.0%, respectively. Radiation therapy appeared to have a beneficial effect on some men: 54.1% of men with minimal incontinence became completely continent of urine during follow-up. Of those with significant urinary incontinence, 29.7% reported resolution and 27.0% reported improved symptoms with no requirement for pads. Of the 1276 men with moderate IPSS, the mean IPSS decreased from 12 to 9.8 at the time of the last follow-up (P < .001). Similarly, of the 233 men with severe IPSS, the mean IPSS decreased from 24 to 13 at the time of the last follow-up (P < .001). CONCLUSION: IG-IMRT for clinically localized CaP is associated with a relatively low incidence of urinary incontinence. Although unexplained, IG-IMRT seems to improve symptoms in some men with baseline urinary incontinence and moderate-to-severe IPSS.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Salami SS, Obedian E, Zimberg S, et al. Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer. Adv Radiat Oncol. 2016. PMID: 28740902. doi:10.1016/j.adro.2016.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。